News
The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...
Evidence-based medicine "Boy Wonder" Dr. Vinay Prasad was fired as CBER Director after less than three months on the job.
Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...
Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset ...
Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine
It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former ...
Hosted on MSN1d
WSJ Opinion: A Shakeup at the FDAJournal Editorial Report: Vinay Prasad exits after gene-therapy reversal. Why Britain faces a bigger Trump tariff blow ...
Vinay Prasad’s ouster as the Food and Drug Administration’s top vaccine and gene therapy regulator came after frustration ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results